Amaria, R., Reddy, S., Tawbi, H., Davies, M., Ross, M., Glitza, I., Cormier, J., Lewis, C., Hwu, W., Hanna, E., Diab, A., Wong, M., Royal, R., Gross, N., Weber, R., Lai, S., Ehlers, R., Blando, J., Milton, D., Woodman, S., Kageyama, R., Wells, D., Hwu, P., Patel, S., Lucci, A., Hessel, A., Lee, J., Gershenwald, J., Simpson, L., Burton, E., Posada, L., Haydu, L., Wang, L., Zhang, S., Lazar, A., Hudgens, C., Gopalakrishnan, V., Reuben, A., Andrews, M., Spencer, C., Prieto, V., Sharma, P., Allison, J., Tetzlaff, M., & Wargo, J. (2018). neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature medicine, 24, 1649–1654. http://access.bl.uk/ark:/81055/vdc_100086830582.0x0001d1